Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
Yoshiyuki Kanazawa
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorCorresponding Author
Norio Hayashi M.D.
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
First Department of Medicine, Osaka University School of Medicine, 2–2 Yamadaoka, Suita, Osaka 565, Japan===Search for more papers by this authorEiji Mita
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorDr. Tiancheng Li
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorHideki Hagiwara
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorAkinori Kasahara
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorHideyuki Fusamoto
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorTakenobu Kamada
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorYoshiyuki Kanazawa
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorCorresponding Author
Norio Hayashi M.D.
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
First Department of Medicine, Osaka University School of Medicine, 2–2 Yamadaoka, Suita, Osaka 565, Japan===Search for more papers by this authorEiji Mita
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorDr. Tiancheng Li
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorHideki Hagiwara
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorAkinori Kasahara
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorHideyuki Fusamoto
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorTakenobu Kamada
First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan
Search for more papers by this authorAbstract
The quasispecies nature of hepatitis C virus genome distribution is most evident in hypervariable regions of the putative envelope 2 domain. Eight patients with chronic hepatitis C treated with interferon-α were studied as to heterogeneity of the hypervariable regions to clarify the implications of quasispecies. More than 10 recombinant clones generated from polymerase chain reaction-amplified products of the hypervariable regions were sequenced. The sets of clones derived from long-term responders before interferon therapy showed a significantly lower (p < 0.05) degree of sequence complexity of the hypervariable region 1 quasispecies than those from short-term ones or nonresponders. The values of nucleotide diversity (the average number of nucleotide differences per site between two randomly chosen sequences) in hypervariable region 1 before interferon therapy were also significantly lower (p < 0.05) for long-term responders (mean, 2.31 × 10) than for short-term ones or nonresponders (13.02 × 10−2). In some cases, nucleotide diversity decreased remarkably during interferon therapy, whereas the values remained unchanged in other cases. In one interesting case, a short-term response was first noted with the nucleotide diversity decreasing from 13.98 × 10−2 to 0.21 × 10−2; namely, the diversity of the quasispecies was significantly reduced, and then a long-term response was observed after an additional course of interferon therapy. Thus, the degree of quasispecies' complexity and diversity of hypervariable region 1 was closely correlated with the responsiveness to interferon therapy in chronic hepatitis C patients, and thus may have some influence on interferon efficacy. (Hepatology 1994;20:1121–1130).
References
- 1 Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575–1578.
- 2 Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, Fusamoto H, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992; 15: 37–41.
- 3 Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–1506.
- 4 Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–1510.
- 5 Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–397.
- 6 Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877–883.
- 7 Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293–299.
- 8 Domingo E, Martinez-Salas E, Sobrino F, de la Torre JC, Portela A, Ortin J, Lopez-Galindez C, et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance—a review. Gene 1985; 40: 1–8.
- 9 Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol 1987; 41: 409–433.
- 10 Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225–3229.
- 11 Kew OM, Nottay BK. Evolution of the oral polio vaccine strains in humans occurs by both mutations and intramolecular recombination. In: RM Chanock, RA Lerner, eds. Modern approaches to vaccines. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1984: 357–367.
- 12 Mateu MG, Martinez MA, Rocha E, Andreu E, Parejo J, Giralt E, Sobrino F, et al. Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A 1989; 86: 5883–5887.
- 13 Parry N, Fox G, Rowlands D, Brown F, Fry E, Acharya R, Logan D, et al. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature 1990; 347: 569–572.
- 14 Salvato M, Borrow P, Shimomaye E, Oldstone MBA. Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence. J Virol 1991; 65: 1863–1869.
- 15 Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J Virol 1991; 65: 308–312.
- 16 Hijkata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991; 175: 220–228.
- 17 Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842–848.
- 18 Kato N, Ootsuyama Y, Tanaka T, Nakagawa M, Nakazawa T, Muraiso K, Ohkoshi S, et al. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res 1992; 22: 107–123.
- 19 Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992; 89: 3468–3472.
- 20 Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, Tsuda F, et al. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167–177.
- 21 Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, et al. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 1105–1113.
- 22 Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619–624.
- 23 Kwok S, Higuchi R. Avoiding false positivities with PCR. Nature 1989; 339: 237–238.
- 24 Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673–679.
- 25 Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol 1991; 72: 2697–2704.
- 26 Nowak MA, Anderson RM, McLean AR, Wolfs TFW, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science 1991; 254: 963–969.
- 27 Eigen M, Biebricher CK. Sequence space and quasispecies distribution. In: RNA Genetics. Boca Raton: CRC Press, 1988: 211–245.
- 28 Hamming RW. Coding and information theory. Englewood Cliffs: Prentice-Hall, 1980.
- 29 Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc Natl Acad Sci U S A 1979; 76: 5269–5273.
- 30 Gojobori T, Ishii K, Nei M. Estimation of average number of nucleotide substitutions when the rate of substitution varies with nucleotide. J Mol Evol 1982; 18: 414–423.
- 31 Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986; 3: 418–426.
- 32 Wolinsky SM, Wike CM, Korber BTM, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255: 1134–1137.
- 33 Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJL. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol 1990; 64: 5840–5850.
- 34 Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA, Brown AJL. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyteassociated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991; 65: 6266–6276.
- 35 Weiland E, Stark R, Haas B, Rumenapf T, Meyers G, Thiel HJ. Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol 1990; 64: 3563–3569.
- 36 Rumenapf T, Stark R, Meyers G, Thiel HJ. Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity. J Virol 1991; 65: 589–597.
- 37 Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986; 233: 209–212.
- 38 Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 1986; 234: 1392–1395.
- 39 Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp 160 recognized by class I major histocompatibility complex moleculerestricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1988; 85: 3105–3109.
- 40 Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67: 3923–3930.
- 41
Nei M.
Molecular evolutionary genetics.
New York:
Columbia University,
1987.
10.1111/j.1365-294X.2006.02908.x Google Scholar
- 42 Sheppard HW, Gutman GA. Allelic forms of rat chain genes: evidence for strong selection at the level of nucleotide sequence. Proc Natl Acad Sci U S A 1981; 78: 7064–7068.
- 43 Hughes AL, Nei M. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 1988; 335: 167–170.
- 44 Li WH, Wu CI, Luo CC. A new method for estimating synonymous and nonsynonymous rates of nucleotide substitution considering the relative likelihood of nucleotide and codon changes. Mol Biol Evol 1985; 2: 150–174.
- 45 Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914–915.